Featured Issue Briefs
The Battle on the Home Front: Jonathan Gadsden's Story
Marine Lance Corporal's story reflects the growing need for new antibiotics that can treat dangerous diseases, against which most drugs are useless. Read More
Facilitating Medical Device Innovation: De Novo Reform
The de novo process -- which requests lower-risk reclassification of medical devices and entry into the marketplace -- as it exists now is not achieving its purpose and has instead added unnecessary and time-consuming requirements. Read More
Food Products Recalled by FDA
Since President Obama signed the FDA Food Safety Modernization Act into law, at least 149 FDA-regulated food products have been recalled due to potential pathogenic contamination. Read More
More Issue Briefs
| Date | Issue Briefs | Topic |
|---|---|---|
| Mar 1, 2012 |
MRSA on the Appalachian Trail: The Story of Steve WeiselHiking the Appalachian Trail, Steve Weisel thought little of the blisters on his feet until he discovered they were infected with life-threatening methicillin-resistant Staphylococcus aureus (MRSA) -- an increasingly common "superbug" that does not respond to first-line antibiotics. Mr. Weisel's story demonstrates the urgent need for new and innovative therapies to treat this growing threat. More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Threat of Multidrug-Resistant Infections to ChildrenExpert testimony, research, and commentary More info |
Antibiotic Innovation |
| Mar 1, 2012 |
When Multiple Bugs Strike: The Story of Alice BrennanA healthy immune system may be all the protection someone needs to overcome a bacterial infection, but once one disease takes hold, it may beget more illnesses. Such is often the case with Clostridium difficile, a potentially deadly bacterium that can flourish in the wake of other infections. Senior citizens, such as Alice Brennan, are particularly vulnerable and serve as a reminder that new and powerful antibiotics are needed as protection from dangerous bacterial threats. More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Superbug ThreatAs Drug-resistant bacteria spread, the pipeline for antibiotics is drying up More info |
Antibiotic Innovation |
| Mar 1, 2012 |
The Threat of Multidrug-Resistant Infections to the U.S. MilitaryExpert Testimony, Research, and Commentary Learn More “MDRO multidrug resistant organism infections have become an international health problem during the past several decades and now pose a challenge to the care of our wounded military personnel.” — D. Hospenthal More info |
Antibiotic Innovation |
| Jan 2, 2012 |
Patient Story: Jamel Sawyer: A Young Man Fights MRSAOne of the most notorious multidrug-resistant superbugs, MRSA is responsible for an estimated 19,000 deaths and 360,000 hospitalizations each year in this country. Jamel’s story illustrates the twin dangers presented by emerging multidrug-resistant bacterial infections and the waning effectiveness and availability of drugs to treat them. More info |
Antibiotic Innovation |
| Sep 20, 2011 |
National Headlines Reporting on the Need for New, Lifesaving AntibioticsNational and international headlines warn that multidrug-resistant superbugs are on the rise and the pipeline of new antibiotics is running dry. More info |
Antibiotic Innovation |
| Sep 20, 2011 |
What Leading Experts are Saying about Emerging Drug-Resistant Infections and the Need for New Drugs to Treat ThemLegislators, regulators, scientists and academics agree: we are running out of antibiotics to treat drug-resistant infections—and we need new ones now. Here is what leading voices are saying about how economic, scientific and regulatory factors are impeding the development of new antibiotics, and what we can do about it. More info |
Antibiotic Innovation |
| Sep 20, 2011 |
Bill Summary: The Generating Antibiotic Incentives Now Act (H.R. 2182)The Generating Antibiotic Incentives Now (GAIN) Act of 2011 (H.R. 2182) seeks to create incentives to encourage the development of products to treat, prevent, detect and diagnose antibiotic-resistant infections. It extends the length of time an approved drug is free from competition and clarifies the regulatory pathway for new antibiotics. More info |
Antibiotic Innovation |
| Apr 12, 2012 |
Reviving the Pipeline of Life-Saving AntibioticsAntibiotic-resistant infections are a growing public health threat. At the same time, antibiotic innovation is waning. Pew, the IIDSA and PhRMA hosted a one-day conference, Reviving the Pipeline of Life-Saving Antibiotics: Exploring Solutions to Spur Innovation on September 22, 2011, exploring ways to overcome the challenges that hinder the development of new antibiotics. More info |
Drug Safety, Antibiotic Innovation |
